63 results about "Intramuscular injection" patented technology

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

The application discloses a rat fixing device based on biological evaluation of medical instruments. The device comprises an operation panel, a fixing cover, a sliding sheet and a sliding groove. A rectangular opening is designed in the center of the base of the operation panel, which is specially used for abdominal cavity injection operation of rats. The rat fixing cover is divided into four sections and is arranged on the operation panel. The two sides of the fixing cover are provided with the sliding sheets. The shape of the two sliding sheets after being spliced together is the same as that of the fixing cover. The lower end of the sliding sheet is in contact with the operation panel, and the sliding groove is arranged at the contact part. The rat fixing device can effectively adjust the size, so that rats with different body types can be effectively fixed, and the smooth operation of the test is ensured. The device is convenient to operate and stable in rat fixing.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention discloses a PKPD-guided method for treating porcine Pasteurella multocida with antibiotics. YDMS injection is used as the antibiotic, administered intramuscularly to pigs infected with Pasteurella multocida. The dosing regimen is adjusted based on in vivo PK / PD target values. The minimum inhibitory concentration (MIC) of YDMS against Pasteurella multocida is 0.06 μg / mL. PK / PD monitoring is performed using a combination of colloidal gold rapid detection and quantitative real-time PCR. This invention clarifies the three-level PK / PD target values ​​of YDMS against Pasteurella multocida and uses AUIC as the core quantitative indicator, avoiding the blindness of traditional empirical dosing. This ensures precise matching of drug concentration and infection severity, effectively reducing the risk of infection aggravation due to insufficient medication or cumulative toxicity caused by overdose, and significantly improving the consistency of treatment efficacy.

The utility model relates to the technical field of injectors, in particular to a clinical intramuscular injection universal injector which comprises an injection sleeve, a needle head arranged at one end of the injection sleeve, a piston connected to the injection sleeve in a sliding mode, a push rod with one end extending into the injection sleeve to be connected with the piston and a push head arranged at the end of the push rod. The fixed sleeve is fixed to the injection sleeve, the movable sleeve is detachably connected to the fixed sleeve, one end of each support is connected with the movable sleeve, the three supports are arranged in a triangular shape, and when two thirds of the needle head is inserted into the human body, the bottom ends of the three supports abut against the skin of the human body; according to the intramuscular injection needle, the insertion depth of the needle head can be guaranteed, the needle head can be effectively prevented from being continuously immersed into the skin in the propelling injection process, the situation that the injection position is inclined is avoided, the difficulty of clinical intramuscular injection is reduced, and the intramuscular injection effect is guaranteed.

The application discloses a recombinant adenovirus vector tumor vaccine and a preparation method and application thereof, wherein the antigen coded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of more than two antigen peptide epitopes of KRAS protein. The recombinant adenovirus vector tumor vaccine of the application codes multiple KRAS tumor-specific antigen peptides, and has a good killing effect on KRAS mutation-driven tumors, especially lung tumors. The vaccine can be inhaled in a form of atomization, injected into muscles first and then inhaled in a form of atomization, inhaled in a form of atomization first and then injected into muscles, injected into muscles, or simultaneously injected into muscles and administered in a form of atomization. After atomization, the vaccine can be inhaled through a nasal cavity or an oral cavity to reach the lungs, generate an anti-tumor protective immune response on the respiratory tract, the lungs and the whole body, and enhance the utilization rate and the treatment effect of the vaccine.

The invention relates to the technical field of aquaculture and biology, in particular to an SIFamide neuropeptide gene and application of the SIFamide neuropeptide gene in promoting growth of litopenaeus vannamei. The litopenaeus vannamei SIFamide gene is shown as a nucleotide sequence of SEQ ID NO: 1. The SIFamide neuropeptide gene is applied to the growth and intestinal peristalsis of the litopenaeus vannamei. The nucleotide sequence of the interference fragment for inhibiting the SIFamide neuropeptide gene is as shown in SEQ ID NO: 4. After the nucleotide sequence (double-stranded RNA) of the interference fragment is applied to the litopenaeus vannamei in an intramuscular injection manner, the weight increase of the litopenaeus vannamei is obviously accelerated and the intestinal peristalsis frequency is obviously improved under the condition that the expression of the SIFamide gene is inhibited. According to the method, damage to the litopenaeus vannamei is small, normal ingestion, molting, inhabiting and other behaviors of the litopenaeus vannamei are not affected, and the action effect is stable.

The utility model relates to an efficient poultry vaccine intramuscular injection device which comprises an obliquely-arranged stepping support and a PLC, an injection device and a propelling device are arranged on the front end face of the stepping support, one end of the injection device is connected with the propelling device, a neck fixing device is arranged at one end of the stepping support, and the other end of the stepping support is connected with the PLC. The neck fixing device comprises a first connecting piece, a second connecting piece and a neck fixing frame arranged on the first connecting piece, the second connecting piece is connected with the stepping support, the bottom end of the second connecting piece is hinged to the first connecting piece, a proximity switch is arranged on the second connecting piece, and the neck fixing frame is connected with the neck fixing frame in a non-external force state. One side of the top end face of the hinged first connecting piece is attached to the inner wall of the second connecting piece, the proximity switch is far away from the side edge of the first connecting piece, the side edge of the first connecting piece abuts against the proximity switch in the state that the first connecting piece is lifted upwards under external force, and through the arrangement of the proximity switch, the advantages of being high in injection efficiency and low in cost are achieved.

The invention discloses an environment-friendly enzyme formula and a farm odor treatment technology, which comprise an environment-friendly enzyme formula and a farm odor treatment technology, and are characterized in that the environment-friendly enzyme formula comprises a simple kitchen waste environment-friendly enzyme, a farm special deodorization environment-friendly enzyme and a tea seed shell Chinese honeylocust fruit environment-friendly enzyme; the farm odor treatment technology comprises livestock and poultry house spraying deodorization, excrement concentration area deodorization and long-term maintenance deodorization. According to the environment-friendly enzyme formula and the farm odor treatment technology thereof, the death rate of piglets is greatly reduced. Skin diseases of piglets are the most headache in farms every winter and spring, and the development of epidemic diseases can be controlled only by using a large amount of antibiotics every morbidity. Casualties are still caused when the number is used up by external spraying, oral administration and intramuscular injection, and the death rate is up to 30% in severe cases. The environment-friendly enzyme is sprayed once in the breeding house every day or once every other day, so that the death rate of the piglets is reduced from original 5% to 1%.

The present application relates to the technical field of pharmaceutical cocrystal, and specifically discloses a callylazine and quercetin pharmaceutical cocrystal, a preparation method and application thereof, wherein callylazine and quercetin are mixed in proportion, a good solvent n-propanol is added until complete dissolution, a poor solvent is added drop by drop into the mixed solvent until a supersaturated state, a mixed solution is obtained, solvent in the mixed solution is volatilized by using a solvent evaporation crystallization method, intermolecular hydrogen bonding of callylazine and quercetin is formed, and a callylazine and quercetin pharmaceutical cocrystal is obtained. The powder dissolution experiment result of the callylazine and quercetin cocrystal shows that the dissolution rate of callylazine decreases under neutral conditions compared with the release rate of free drug, and potential sustained release effect is shown, so that the callylazine and quercetin pharmaceutical cocrystal can be prepared into a muscle injection, and has potential for long-acting treatment of schizophrenia and reduction of muscle stimulation.

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a psychiatric or nervous system disorder in mothers of children 18 months of age or younger, wherein the 5-MeO-DMT or the pharmaceutically acceptable salt thereof is administered via an intravenous, intramuscular, or subcutaneous route.

This invention discloses a bubble-soluble microneedle patch for delivering mRNA, its preparation method, and its applications. The bubble-soluble microneedle patch includes a base and an array of soluble microneedles on the base, with bubbles present at the connection between the base and the soluble microneedles. The soluble microneedles comprise a soluble polymer material and lipid nanoparticles carrying mRNA, providing a novel delivery method for mRNA. The bubble-soluble microneedle patch provided by this invention solves the problem of lipid nanoparticle accumulation in the liver and subsequent side effects caused by traditional intramuscular injection of mRNA vaccines. It also solves the problem of low-temperature storage of mRNA vaccines, allowing the resulting soluble microneedle patch to be stored at room temperature. It can efficiently deliver mRNA to lymphatic organs and to the subcutaneous dermis rich in antigen-presenting cells (APCs), thereby inducing a strong immune response in vivo.

The invention discloses preparation and application of a nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system, and belongs to the technical field of biological medicine. The nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is composed of lipid nanoparticles, a nucleic acid drug and nucleotide / nucleoside / base / ribose / deoxyribose, exogenous nucleotide components are tightly combined with the nucleic acid drug through hydrogen-bond interaction and base stacking force, the stability and translation efficiency of mRNA are enhanced, and the delivery effect of the nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is improved. And then loading the two into the lipid nano-particles through electrostatic interaction. The delivery system has significant advantages in improving the entrapment efficiency, stability, transfection efficiency and cell survival rate of nucleic acid drugs, can be delivered through intravenous administration, intramuscular injection, aerosol inhalation and the like, can significantly improve the disease treatment efficiency, and has wide clinical application prospects.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

The invention relates to a compound emulsion for preventing and controlling bovine viral diarrhea. Every 100 g of the compound emulsion comprises the following components by weight: 0.1 to 6.0 g of bovine viral diarrhea antibody, 2.0 to 4.0 g of solanum nigrum polysaccharide, 0.1 to 1.0 g of donaxine, 0.1 to 5.0 g of taurine, 1.0 to 3.0 g of ephedra oil, 4.0 to 10.0 g of polyoxyethylene (40) castor oil, 10.0 to 18.0 g of linoleic acid, 14.0 to 20.0 g of ethyl oleate, 15.0 to 25.0 g of span-40, and the balance of water for injection. Primary emulsion of the reemulsion is in an oil-in-water (O / W) type, and secondary emulsion of the reemulsion is in an oil-water mutual wrapping type. The invention further discloses a preparation method, the process controllability is high, and low-cost production is facilitated. The reemulsion can play a slow-release and long-acting role after intramuscular injection, the effective concentration of the antibody can be maintained in vivo for a long time, repeated medication is not needed, the stress reaction of animals is reduced, meanwhile, viruses are neutralized more thoroughly, the overall curative effect is remarkably improved, and the treatment cycle is shortened.

This invention discloses a macromolecular JAK inhibitor, its preparation method, and its applications. This macromolecular JAK inhibitor is an anti-inflammatory amphiphilic polymer of hexachlorocyclotriphosphazene or cyanuric chloride coupled with different functional groups. The anti-inflammatory amphiphilic polymer is synthesized with hexachlorocyclotriphosphazene or cyanuric chloride as the backbone structure, linked by a stepwise nucleophilic substitution reaction with different proportions of hydrophilic modules polyethylene glycol and 3-aminobenzoyl hydrazide (i.e., luminol). The preparation method of this type of anti-inflammatory macromolecular drug is simple, its structure and function are controllable, and it is easy to synthesize on a large scale. Furthermore, this type of amphiphilic anti-inflammatory macromolecular drug can self-assemble into nanomicelles in aqueous solution through intermolecular interactions. It can be applied to the treatment of various acute and chronic inflammations or diseases related to the JAK signaling pathway, and can be administered via intravenous injection, subcutaneous injection, nebulized inhalation, intramuscular injection, and any combination of the above methods. This anti-inflammatory macromolecular drug has significant therapeutic effects in acute lung injury, acute kidney injury, acute liver failure, sepsis, and asthma.

This invention provides a method for preparing influenza virus hemagglutinin protein HA and its application, belonging to the field of biopharmaceutical technology. The method utilizes engineered cell chassis cells with glycosylation modification capabilities. After fermentation expression, the expressed protein from the engineered cells is extracted in a single step to obtain a crude extract containing the target antigen. The crude extract obtained from the engineered cells constructed in this invention, after induction, has the potential to serve as a candidate for a dual-route vaccine (intramuscular injection and mucosal immunization), providing a new technical approach for the multi-route immunization development of influenza vaccines.

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used to treat patients suffering from postpartum depression (PPD), where 5-MeO-DMT is administered via intravenous, intramuscular, or subcutaneous routes.

The present application provides an amide compound and a use thereof. The amide compound is selected from a compound represented by formula (I), a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, an atropisomer thereof, or a pharmaceutically acceptable salt thereof. In the present application, a series of novel amide compounds is developed. These amide compounds have excellent anti-HIV activity, no significant cytotoxicity, relatively strong affinity for HIV-1 capsid protein, and good specificity, are suitable for intravenous administration, oral administration, subcutaneous administration, and intramuscular injection administration, and show relatively long half-life and relatively high exposure in vivo. In addition, the amide compounds have no significant inhibitory effect on various CYP enzymes, exhibit high plasma protein binding, and have excellent safety and good metabolic stability in vivo, no potential off-target effect, high safety, and the potential to be developed into clinical long-acting drugs.

The invention belongs to the technical field of biology, and discloses an application of Compound C in inhibition of uterine contraction of sheep, the Compound C significantly reduces expression of autophagy related genes LC3, BECN1, ATG5 and ATG7 by regulating an AMPK / mTOR signal channel, further inhibits autophagy of sheep uterine smooth muscle cells, and realizes targeted inhibition of uterine contraction. The optimal concentration of the Compound C in the preparation is 10 <-6 > mol / L, the administration dosage is 0.01 mg / kg of sheep body weight, the administration mode is intramuscular injection, and the Compound C can be combined with oxytocin to reverse the uterine contraction promoting effect of oxytocin. Cell experiments and animal experiments prove that the Compound C can improve uterine smooth muscle cell ultramicrostructure disorder, reduce autophagosome formation, delay the recovery speed of uterine horn of postpartum sheep, effectively inhibit abnormal uterine contraction and provide a new strategy for pregnancy maintenance and abortion reduction, and the action is milder.

The invention discloses an antioxidant-free kanamycin injection and a preparation method thereof.The injection is composed of kanamycin sulfate, a pH regulator and water for injection, the pH is 4.5-7.0, headspace oxygen is controlled to be smaller than or equal to 1% through nitrogen charging, and the injection is completely free of sodium hydrogen sulfite, cysteine hydrochloride and other antioxidants and can be used for intravenous drip and intramuscular injection; the invention further provides a preparation process and an ion chromatography verification method which are compatible with an existing production line, and the product quality meets the requirements of Chinese Pharmacopoeia 2020 through high temperature, strong light and long-term stability test verification; clinical retrospective analysis shows that the rash occurrence rate is reduced to 3.1% from 27.3%, the safety is remarkably improved while the medicine quality is ensured, and the method has a good industrial application prospect.

The application discloses a preparation method of rabies virus glycoprotein and application thereof, and belongs to the technical field of biological medicines, and comprises the following steps: expressing a glycoprotein G gene of rabies virus containing an extramembrane region, a transmembrane region and an intramembrane region in yeast; performing cell disruption on the yeast, adding a detergent, and obtaining a solution containing rabies virus glycoprotein G; purifying the solution to obtain full-length rabies virus glycoprotein G; and immunizing the prepared full-length rabies virus glycoprotein G through intramuscular injection, oral administration or atomization inhalation. The scheme provided by the application has the advantages of strong immunogenicity, high safety, low production cost and easiness in scaling, solves the problems of complex traditional vaccine process and high cost, and provides a reliable new type of subunit vaccine solution for rabies prevention.